Pilot Radioimmunotherapy Trial with 131I-labeled Murine Monoclonal Antibody CC49 and Deoxyspergualin in Metastatic Colon Carcinoma Academic Article uri icon


  • An antimouse immune response is invariable following administration of murine monoclonal antibody (mAb), precluding effective multidose therapy. In advanced colorectal cancer patients, we carried out a pilot study with multiple doses of 131I-labeled CC49 administered with deoxyspergualin (DSG), an immunomodulator, to determine its effect on immune response. Cumulative toxicity and efficacy were also evaluated. Six patients with tumor-associated glycoprotein 72-expressing colorectal cancer were treated i.v. with 15 mCi/m2 131I-labeled to 20 mg mAb CC49 biweekly, along with concurrent DSG 200 mg/m2 daily for 5 days, for a maximum of four courses. None had received prior murine mAbs. All patients had targeting of radioactivity to known tumor sites following initial infusion. Four of six patients received all four courses of therapy, three without any acute side effects. In these patients, there was no change in serum clearance with variable tumor targeting following repeat infusions. Two patients had


  • Divgi, CR
  • Scott, AM
  • Gulec, S
  • Broussard, EK
  • Levy, N
  • Young, C
  • Capitelli, P
  • Daghighian, F
  • Williams, JM
  • Finn, RD
  • Kemeny, N
  • Hilton, S
  • Kelsen, D
  • Milenic, DE
  • Lora, ME
  • Schlom, J
  • Larson, SM

publication date

  • August 1, 1995